You are here

Botox

Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst

Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst

Fierce Pharma

Flag link:

Allergan unveils new Botox plant ahead of $63B AbbVie merger

Allergan unveils new Botox plant ahead of $63B AbbVie merger

Fierce Pharma

drug manufacturing

Flag link:

Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says

Should AbbVie break up Allergan? If it wants to make up for Humira, then yes, analyst says

Fierce Pharma

Flag link:

AbbVie may count on Allergan's Botox for post-merger growth. But what else?

AbbVie may count on Allergan's Botox for post-merger growth. But what else?

Fierce Pharma

Flag link:

Allergan’s Botox Approved for Lower Limb Spasticity in Pediatric Patients

Allergan’s Botox Approved for Lower Limb Spasticity in Pediatric Patients

BioSpace

lower limb spasticity

Flag link:

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending

Fierce Pharma

Gilead Sciences

Flag link:

Whoops! Allergan's bid to shield Botox manufacturing secrets from competitors backfires

Whoops! Allergan's bid to shield Botox manufacturing secrets from competitors backfires

Fierce Pharma

Flag link:

AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?

AbbVie’s $63B Allergan buyout offer depends on Botox growth. But will it last?

Fierce Pharma

Flag link:

5 reasons AbbVie bought Allergan, and why they may not be enough

5 reasons AbbVie bought Allergan, and why they may not be enough

Biopharma Dive

diversification

Flag link:

Allergan’s Botox Approved for Pediatric Limb Spasticity Amid Split-Up Rumors

Allergan’s Botox Approved for Pediatric Limb Spasticity Amid Split-Up Rumors

Endpoints

upper limb spasticity

Flag link:

Allergan Rises After FDA Accepts License Applications for Botox Supplements

Allergan Rises After FDA Accepts License Applications for Botox Supplements

TheStreet.com

Flag link:

Evolus' Botox competitor is here. Will it dent Allergan's sales?

Evolus' Botox competitor is here. Will it dent Allergan's sales?

Fierce Pharma

Flag link:

Even with new competition, Botox can hold its own in growing migraine field: Allergan executives

Even with new competition, Botox can hold its own in growing migraine field: Allergan executives

Fierce Pharma

Teva Pharmaceuticals

Flag link:

Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical

Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical

Fierce Pharma

Teva Pharmaceutical

Flag link:

Could synthetic Botox soothe chronic pain? A new study holds out the possibility

Could synthetic Botox soothe chronic pain? A new study holds out the possibility

Stat

Flag link:

FDA stiff arms Evolus’ rival to Allergan’s blockbuster Botox, but execs promise a snap response

FDA stiff arms Evolus’ rival to Allergan’s blockbuster Botox, but execs promise a snap response

Endpoints

Flag link:

Allergan's Botox sets its sights on a new customer: men

Allergan's Botox sets its sights on a new customer: men

Medical Marketing and Media

DTC advertising

Flag link:

Botox Biosimilar in Development by Mylan and Revance Therapeutics

Botox Biosimilar in Development by Mylan and Revance Therapeutics

Xtalks

Revance Therapeutics

Flag link:

Mylan teams up with Revance on biosimilar for Botox

Mylan teams up with Revance on biosimilar for Botox

Reuters

Flag link:

Pages